Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Brooks

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncogene|April 21, 2025
Therapeutic targeting of the p300/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapyJinghui Liu, Xinyi Wang, Daheng He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPaul K Paik, Ronglai Shen, Michael F Berger, et al.
Immunity|September 15, 2019
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in LymphomaStefanie N Meyer, Claudio Scuoppo, Sofija Vlasevska, et al.
International Journal of Oncology|January 17, 2009
Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancerLucy J Knight, Joseph Burrage, Sarah R Bujac, et al.
Nature Communications|October 19, 2021
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesisJeannine Diesch, Marguerite-Marie Le Pannérer, René Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft modelsJingchuan Zhang, Lin Zhang, Xinying Su, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Oncogene|September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Cancer Cell|November 23, 2023
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesLuciano Nicosia, Gary J Spencer, Nigel Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncogene|April 21, 2025
Therapeutic targeting of the p300/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapyJinghui Liu, Xinyi Wang, Daheng He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2017
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung CancersPaul K Paik, Ronglai Shen, Michael F Berger, et al.
Immunity|September 15, 2019
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in LymphomaStefanie N Meyer, Claudio Scuoppo, Sofija Vlasevska, et al.
International Journal of Oncology|January 17, 2009
Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancerLucy J Knight, Joseph Burrage, Sarah R Bujac, et al.
Nature Communications|October 19, 2021
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesisJeannine Diesch, Marguerite-Marie Le Pannérer, René Winkler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2012
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft modelsJingchuan Zhang, Lin Zhang, Xinying Su, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Oncogene|September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
Cancer Cell|November 23, 2023
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesLuciano Nicosia, Gary J Spencer, Nigel Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2013
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancerRobert H Bradbury, David G Acton, Nicola L Broadbent, et al.
Pageof 3